GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070591 | Oral cavity | LP | chromosome segregation | 117/4623 | 346/18723 | 7.61e-05 | 9.91e-04 | 117 |
GO:004578612 | Oral cavity | LP | negative regulation of cell cycle | 127/4623 | 385/18723 | 1.33e-04 | 1.53e-03 | 127 |
GO:004593012 | Oral cavity | LP | negative regulation of mitotic cell cycle | 83/4623 | 235/18723 | 1.62e-04 | 1.82e-03 | 83 |
GO:000020915 | Oral cavity | LP | protein polyubiquitination | 82/4623 | 236/18723 | 3.23e-04 | 3.26e-03 | 82 |
GO:190198712 | Oral cavity | LP | regulation of cell cycle phase transition | 126/4623 | 390/18723 | 3.69e-04 | 3.64e-03 | 126 |
GO:004593115 | Oral cavity | LP | positive regulation of mitotic cell cycle | 46/4623 | 121/18723 | 7.65e-04 | 6.80e-03 | 46 |
GO:000081911 | Oral cavity | LP | sister chromatid segregation | 70/4623 | 202/18723 | 9.20e-04 | 7.82e-03 | 70 |
GO:000709311 | Oral cavity | LP | mitotic cell cycle checkpoint | 48/4623 | 129/18723 | 1.03e-03 | 8.67e-03 | 48 |
GO:00458391 | Oral cavity | LP | negative regulation of mitotic nuclear division | 22/4623 | 48/18723 | 1.14e-03 | 9.32e-03 | 22 |
GO:007097911 | Oral cavity | LP | protein K11-linked ubiquitination | 15/4623 | 29/18723 | 1.55e-03 | 1.20e-02 | 15 |
GO:190199112 | Oral cavity | LP | negative regulation of mitotic cell cycle phase transition | 62/4623 | 179/18723 | 1.76e-03 | 1.34e-02 | 62 |
GO:001094811 | Oral cavity | LP | negative regulation of cell cycle process | 95/4623 | 294/18723 | 1.80e-03 | 1.37e-02 | 95 |
GO:00517841 | Oral cavity | LP | negative regulation of nuclear division | 24/4623 | 56/18723 | 2.17e-03 | 1.58e-02 | 24 |
GO:190198912 | Oral cavity | LP | positive regulation of cell cycle phase transition | 42/4623 | 115/18723 | 3.06e-03 | 2.09e-02 | 42 |
GO:190198811 | Oral cavity | LP | negative regulation of cell cycle phase transition | 80/4623 | 249/18723 | 4.63e-03 | 2.94e-02 | 80 |
GO:000007511 | Oral cavity | LP | cell cycle checkpoint | 57/4623 | 169/18723 | 5.05e-03 | 3.14e-02 | 57 |
GO:004828511 | Oral cavity | LP | organelle fission | 145/4623 | 488/18723 | 6.02e-03 | 3.57e-02 | 145 |
GO:00988131 | Oral cavity | LP | nuclear chromosome segregation | 88/4623 | 281/18723 | 6.72e-03 | 3.91e-02 | 88 |
GO:190199211 | Oral cavity | LP | positive regulation of mitotic cell cycle phase transition | 34/4623 | 93/18723 | 7.08e-03 | 3.98e-02 | 34 |
GO:00070881 | Oral cavity | LP | regulation of mitotic nuclear division | 39/4623 | 110/18723 | 7.45e-03 | 4.14e-02 | 39 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa041146 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0411411 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0412041 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0516622 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0412051 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0516632 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
hsa05166113 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANAPC1 | SNV | Missense_Mutation | | c.2765N>T | p.Ser922Phe | p.S922F | Q9H1A4 | protein_coding | tolerated(0.07) | benign(0.347) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ANAPC1 | SNV | Missense_Mutation | | c.1549N>A | p.Pro517Thr | p.P517T | Q9H1A4 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | | c.655N>A | p.Glu219Lys | p.E219K | Q9H1A4 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ANAPC1 | SNV | Missense_Mutation | | c.415N>C | p.Glu139Gln | p.E139Q | Q9H1A4 | protein_coding | tolerated(0.29) | benign(0.075) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ANAPC1 | SNV | Missense_Mutation | novel | c.5782N>G | p.Leu1928Val | p.L1928V | Q9H1A4 | protein_coding | tolerated(0.12) | possibly_damaging(0.899) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | | c.5683N>T | p.Pro1895Ser | p.P1895S | Q9H1A4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | novel | c.3620N>A | p.Gly1207Glu | p.G1207E | Q9H1A4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
ANAPC1 | SNV | Missense_Mutation | | c.2563N>A | p.Glu855Lys | p.E855K | Q9H1A4 | protein_coding | tolerated(0.76) | benign(0.04) | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
ANAPC1 | SNV | Missense_Mutation | novel | c.4217T>C | p.Leu1406Pro | p.L1406P | Q9H1A4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | novel | c.2050N>C | p.Glu684Gln | p.E684Q | Q9H1A4 | protein_coding | tolerated(0.07) | benign(0.149) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |